Zydus Lifesciences is right there among the top five gainers on the BSE; from its close of Rs.434, it opened higher today at Rs.444 and soon went on to hit a new 52-week high at Rs.474.85.

The market has obviously has given its Q3FY23 earnings a big thumbs up. Its revenue from operations rose 20% (YoY) at Rs.4362 crore and net profit came in at Rs.623 crore, up 24%.

Its EBITDA margins rose 130 bps to 21.9%.  The US business, which contributes 46% to the total revenue, grew 29% and the India business, which contribute 40% to the sales, rose 12.5%; These two geographies are what led to the company posting these robust numbers.

Its consumer wellness sector, which owns key brands viz. Glucon-D, Nycil and EverYuth (Scrub and Peel-Off), contributing 10% to the revenue, showed a 8% growth though sequentially, it fell 2.5%.